More pep in their step

Peplin Inc. looks to be closing in on the payoff for its migration from Australia to the U.S., with fresh money and management it hopes will take its first product to market.

Since June, the company has completed a private placement, agreed to aquire Neosil Inc., and hired a new CEO. The money will allow it to complete a pair of Phase III trials, the first of which began last week, evaluating topical PEP005 gel for actinic keratosis, with an eye on building out its own commercialization infrastructure in both the U.S. and Australia...